Programs

Developing rapid, targeted and reversible therapies to address unmet needs in stroke and beyond

Programs

Developing rapid, targeted and reversible therapies to address unmet needs in stroke and beyond

PIPELINE

Advancing lead program in acute stroke while exploring additional indications across thrombotic conditions

Targeted, reversible inhibition of von Willebrand Factor (vWF)

BB-031 is an investigational RNA aptamer — a short, structured strand of RNA that folds into a specific 3D shape to bind its target with antibody-like precision. Unlike RNA therapies that alter gene expression, aptamers act as targeted inhibitors that can be rapidly neutralized by a direct-acting reversal agent.

BB-031 selectively and reversibly inhibits von Willebrand Factor (vWF) — a central mediator of clot initiation, growth and stabilization — rather than degrading fibrin, the mechanism used by currently approved fibrinolytic drugs. By binding to vWF with high affinity and selectivity, BB-031 delivers potent inhibition of this key element of clot stabilization, resulting in rapid restoration of blood flow (recanalization).

Together, these properties define a new paradigm in thrombolysis. This vWF-targeted, reversible approach aims to make intervention in thrombotic conditions like acute ischemic stroke safer, more effective and accessible to more patients.

Rapid reversal of
thrombolytic activity

BB-025 is an investigational, rapid-acting oligonucleotide reversal agent that specifically binds to and neutralizes BB-031. Administered as a single intravenous bolus, BB-025 is designed to rapidly and durably reverse BB-031’s thrombolytic activity.

By delivering immediate, durable neutralization of BB-031, BB-025 provides clinicians with a safety mechanism that can reverse BB-031’s thrombolytic activity in the event of bleeding or when urgent surgery is required.

Together, BB-025 and BB-031 enable powerful, targeted thrombolysis with a level of safety and flexibility not possible with current therapies.

disease areas

Focused on thrombotic conditions where rapid, targeted and reversible intervention can change the course of care

Thrombotic events occur when blood clots form inside vessels and restrict blood flow to vital organs. These events can lead to life-threatening conditions, including stroke and heart attack.

stroke

Limitations of Current Therapies for Acute Ischemic Stroke (AIS)

Nearly three decades after the first drug for acute ischemic stroke (AIS) was approved, care remains constrained by time, access and safety limitations — leaving only a small fraction of patients eligible to receive therapy.

Fibrinolytics (tPA and TNK), introduced in 1996, remain the standard of care but are limited by a narrow 3 to 4.5-hour treatment window and a significant bleeding risk that restricts use and physician confidence.

Mechanical thrombectomy, adopted globally in 2015, can extend treatment up to 24 hours, but is limited to patients with large vessel occlusion stroke and is available only in specialized centers—making timely intervention a barrier.

We are committed to advancing a reversible thrombolytic therapy that addresses these limitations and enables healthcare providers to act confidently, quickly and safely.

Clinical trials

Clinical studies evaluating our targeted, reversible approach in stroke

see our ongoing TRIALS

Clinical trials

Clinical studies evaluating our targeted, reversible approach in stroke

see our ongoing studies